Millendo Therapeutics, Inc. (MLND): Price and Financial Metrics
GET POWR RATINGS... FREE!
MLND Stock Summary
- Millendo Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.5% of US listed stocks.
- With a year-over-year growth in debt of 570.28%, Millendo Therapeutics Inc's debt growth rate surpasses 96.28% of about US stocks.
- As for revenue growth, note that MLND's revenue has grown -150.17% over the past 12 months; that beats the revenue growth of only 0.32% of US companies in our set.
- MLND's SEC filings can be seen here. And to visit Millendo Therapeutics Inc's official web site, go to www.ovascience.com.
MLND Stock Price Chart Interactive Chart >
MLND Price/Volume Stats
|Current price||$1.06||52-week high||$2.77|
|Prev. close||$1.12||52-week low||$0.92|
|Day high||$1.13||Avg. volume||1,516,167|
|50-day MA||$1.17||Dividend yield||N/A|
|200-day MA||$1.67||Market Cap||20.19M|
Millendo Therapeutics, Inc. (MLND) Company Bio
Millendo Therapeutics, Inc. provides health care services. The Company develops treatments for endocrine diseases. Millendo Therapeutics serves customers in the United States and France.
MLND Latest News Stream
|Loading, please wait...|
MLND Latest Social Stream
View Full MLND Social Stream
Latest MLND News From Around the Web
Below are the latest news stories about Millendo Therapeutics Inc that investors may wish to consider to help them evaluate MLND as an investment opportunity.
We're starting off the day with a look at the pre-market stock market movers for Wednesday with the biggest winners and losers.
Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COHR, SNX, PFBI, MLND; Shareholders are Encouraged to Contact the Firm
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Coherent, Inc. (NASDAQ: COHR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to II-VI Incorporated for $220.00 in cash and 0.91 shares of II-VI common stock for each Coherent share. If you are a Coherent shareholder, click here to learn more about your rights and options. SY
SHAREHOLDER ALERT: WeissLaw LLP Reminds MLND, DISCA, FOE and MSGN Shareholders About Its Ongoing Investigations
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212) 682-3025(888) [email protected] Millendo Therapeutics, Inc. (NASDAQ: MLND) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CNST, FMBI, SWN, ENVB, MLND; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
MLND Price Returns
Continue Researching MLNDWant to see what other sources are saying about Millendo Therapeutics Inc's financials and stock price? Try the links below:
Millendo Therapeutics Inc (MLND) Stock Price | Nasdaq
Millendo Therapeutics Inc (MLND) Stock Quote, History and News - Yahoo Finance
Millendo Therapeutics Inc (MLND) Stock Price and Basic Information | MarketWatch